Exelixis Inc
—- Market cap
- —
- Debt
- +$399.32M
- Cash
- −$1.06B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: EXEL stock price vs GEF: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at GEF's multiple
Needs GEF P/E.
Implied fair value · at EXEL's multiple
Needs Annual EPS, EXEL P/E.
Metric by metric
Where each company leads, and how wide the gap is.
Price unavailable
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Exelixis Inc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
GREIF, INC. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.18x
1.36x
Net debt / EBITDA
Leverage against operating earnings
-0.70x
3.69x
Cash and equivalents
Liquid reserves on the balance sheet
$1.06B
$197.70M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
EXEL vs AMGN
BIOGEN INC.
EXEL vs BIIB
GILEAD SCIENCES, INC.
EXEL vs GILD
INCYTE CORP
EXEL vs INCY
Sarepta Therapeutics, Inc.
EXEL vs SRPT
SILGAN HOLDINGS INC
EXEL vs SLGN
PACKAGING CORP OF AMERICA
EXEL vs PKG
CROWN HOLDINGS, INC.
EXEL vs CCK
Ardagh Metal Packaging S.A.
EXEL vs AMBP
BALL Corp
EXEL vs BALL
SONOCO PRODUCTS CO
EXEL vs SON
$399.32M
$2.82B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.